THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to ...
PHILADELPHIA—With new competition potentially on its way in the PCSK9 inhibitor class, Amgen's stalwart Repatha is looking for a leg up in treating high-risk heart attack patients. A new analysis ...
--Amgen today announced the presentation of 12 cardiovascular scientific research abstracts, including clinical trial and real-world evidence studies of Repatha ®, that add to the growing body of ...
How do insurance companies decide what medicines to pay for and when to pay for them? Insurers and other payers look first at how well the drug works — not its cost — when they decide whether to cover ...
Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...
The high cost of drugs continues to dominate the news in the biopharmaceutical industry. Recent data for new cancer drugs that upregulate the immune system to fight melanoma, lung cancer, etc. are ...
Q. I developed severe depression while taking Repatha, the injectable cholesterol lowering drug. It took me a horrible nine months to realize the drug was making me suicidal. If I wasn’t sleeping, I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback